AFT Pharmaceuticals Signs Exclusive Japan Deal for Non-Opioid Painkiller
MT Newswires Live06:22
AFT Pharmaceuticals (ASX:AFP, NZE:AFT) entered an exclusive development, licensing, and supply agreement with Japan's Mikasa Seiyaku to develop and commercialize its non-opioid intravenous painkiller Maxigesic IV in Japan, according to a Monday filing with the Australian and New Zealand bourses.
The company will develop and supply the product, while Mikasa will oversee regulatory submissions to Japan's Pharmaceuticals and Medical Devices Agency, obtain marketing authorization and commercialize the treatment, per the filing.
The company will receive an upfront licensing fee, development milestone payments, and royalties on post-launch sales under the agreement, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
